osimertinib has been researched along with Carcinoma* in 2 studies
2 other study(ies) available for osimertinib and Carcinoma
| Article | Year |
|---|---|
Delayed Diagnosis of Lung Carcinoma Presenting as Choroidal Metastasis in a COVID-19 Patient and Initially Treated with Osimertinib.
Topics: Acrylamides; Aniline Compounds; Carcinoma; COVID-19; Delayed Diagnosis; Humans; Lung; Lung Neoplasms | 2022 |
Carcinomatosis under control by osimertinib in
Approximately 25%-30% of patients with non-small cell lung cancer (NSCLC) develop central nervous system (CNS) metastases during the course of the disease; this percentage is higher in patients with epidermal growth factor receptor (EGFR) mutations. Leptomeningeal metastases, infrequent in the advanced setting, have a particularly dismal prognosis. Osimertinib, a third-generation EGFR inhibitor, can provide effective and durable response in this setting.. We present a 62-year-old man with progressive vomiting, headache, short-term memory impairment, and left lower limb hyposthenia. Computed tomography (CT) showed bilateral lung nodules, multiple lymphadenopathies, liver and bone metastases, and CNS and leptomeningeal dissemination, including multiple parenchymal nodules located at supra- and infratentorial brain. Bone needle biopsy documented TTF1+ lung adenocarcinoma. Whole brain radiotherapy (WBRT) and symptomatic treatments were started. Next-generation sequencing reported deletion of exon 19 of. First-line treatment with osimertinib can be safe and effective in Topics: Acrylamides; Aniline Compounds; Biopsy; Carcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Mutation; Protein Kinase Inhibitors; Symptom Assessment; Tomography, X-Ray Computed; Treatment Outcome; Tumor Suppressor Protein p53 | 2021 |